Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$46.36 -0.1%	$39.18	$16.50 ▼ $47.78	$4.31B	N/A	40,693 shs	14,673 shs
IMVT Immunovant	$14.81 0.0%	$16.44	$12.72 ▼ $34.47	$2.58B	0.66	1.46 million shs	1.13 million shs
MLTX MoonLake Immunotherapeutics	$54.21 +2.9%	$49.87	$31.42 ▼ $58.26	$3.48B	1.27	475,254 shs	307,496 shs
SNDX Syndax Pharmaceuticals	$15.77 +2.4%	$10.53	$8.58 ▼ $22.50	$1.36B	0.74	2.25 million shs	1.34 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-2.30%	+15.42%	+14.88%	+84.71%	+4,639,999,900.00%
IMVT Immunovant	-2.88%	-2.56%	-17.25%	+2.85%	-52.45%
MLTX MoonLake Immunotherapeutics	-1.99%	-3.98%	-0.81%	+36.64%	+7.38%
SNDX Syndax Pharmaceuticals	-2.96%	+18.74%	+62.79%	+44.60%	-24.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	3.0396 of 5 stars	4.4	2.0	0.0	0.0	3.0	1.7	0.0
MLTX MoonLake Immunotherapeutics	1.7284 of 5 stars	3.4	1.0	0.0	0.0	1.6	2.5	0.0
SNDX Syndax Pharmaceuticals	4.0458 of 5 stars	4.5	0.0	0.0	4.4	3.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
IMVT Immunovant	2.83	Moderate Buy	$35.20	137.61% Upside
MLTX MoonLake Immunotherapeutics	2.78	Moderate Buy	$74.43	37.30% Upside
SNDX Syndax Pharmaceuticals	3.00	Buy	$38.00	140.99% Upside

Current Analyst Ratings Breakdown

Latest SNDX, MLTX, IMVT, and AAPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/6/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $82.00
8/6/2025	SNDX Syndax Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2025	SNDX Syndax Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$46.00 ➝ $51.00
8/5/2025	SNDX Syndax Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$43.00 ➝ $56.00
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/28/2025	MLTX MoonLake Immunotherapeutics	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/28/2025	MLTX MoonLake Immunotherapeutics	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	4.39	N/A	N/A	$0.48 per share	96.58
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$5.57 per share	N/A
SNDX Syndax Pharmaceuticals	$23.68M	57.36	N/A	N/A	$1.83 per share	8.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.78	N/A	N/A	N/A	N/A	-40.98%	-35.81%	11/6/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.89	N/A	N/A	N/A	-428.48%	-130.47%	-56.12%	11/4/2025 (Estimated)

Latest SNDX, MLTX, IMVT, and AAPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/5/2025	Q2 2025	MLTX MoonLake Immunotherapeutics	-$0.73	-$0.87	-$0.14	-$0.87	N/A	N/A
8/4/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$1.01	-$0.83	+$0.18	-$0.83	$26.64 million	$37.96 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
IMVT Immunovant	N/A	12.32	12.32
MLTX MoonLake Immunotherapeutics	0.21	16.65	16.65
SNDX Syndax Pharmaceuticals	2.06	4.71	4.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
IMVT Immunovant	47.08%
MLTX MoonLake Immunotherapeutics	93.85%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
IMVT Immunovant	1.80%
MLTX MoonLake Immunotherapeutics	12.05%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	92.96 million	N/A	N/A
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.23 million	56.49 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.14 million	82.61 million	Optionable

SNDX, MLTX, IMVT, and AAPG Headlines

Recent News About These Companies

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Acquired by Algert Global LLC

August 19 at 7:00 AM | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Sells $298,368.00 in Stock

August 19 at 4:27 AM | insidertrades.com

Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals

August 18 at 12:10 AM | insidermonkey.com

BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo

August 18 at 2:26 AM | msn.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 4.4% - Time to Buy?

August 16, 2025 | marketbeat.com

Analyzing Syndax Pharmaceuticals (NASDAQ:SNDX) & CNS Pharmaceuticals (NASDAQ:CNSP)

August 16, 2025 | americanbankingnews.com

Syndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted?

August 15, 2025 | finance.yahoo.com

Aigen Investment Management LP Buys Shares of 24,158 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

August 15, 2025 | marketbeat.com

Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?

August 14, 2025 | zacks.com

Investors Purchase Large Volume of Call Options on Syndax Pharmaceuticals (NASDAQ:SNDX)

August 14, 2025 | americanbankingnews.com

Syndax Pharmaceuticals: A Tale Of Two Drug Launches

August 13, 2025 | seekingalpha.com

Syndax Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:SNDX)

August 13, 2025 | marketbeat.com

FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals

August 13, 2025 | insidermonkey.com

Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $36.91

August 13, 2025 | americanbankingnews.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by Brokerages

August 11, 2025 | marketbeat.com

Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts

August 10, 2025 | finance.yahoo.com

What is B. Riley's Forecast for SNDX Q3 Earnings?

August 10, 2025 | americanbankingnews.com

Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth

August 9, 2025 | theglobeandmail.com

Syndax Pharmaceuticals (SNDX) Gets a Buy from Goldman Sachs

August 9, 2025 | theglobeandmail.com

Q3 Earnings Forecast for SNDX Issued By B. Riley

August 9, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by B. Riley

August 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX, MLTX, IMVT, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$46.36 -0.04 (-0.09%)

As of 03:57 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Immunovant NASDAQ:IMVT

$14.81 -0.01 (-0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$14.81 0.00 (-0.02%)

As of 04:10 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

MoonLake Immunotherapeutics NASDAQ:MLTX

$54.21 +1.55 (+2.94%)

Closing price 03:59 PM Eastern

Extended Trading

$53.12 -1.09 (-2.01%)

As of 04:10 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Syndax Pharmaceuticals NASDAQ:SNDX

$15.77 +0.37 (+2.39%)

Closing price 03:59 PM Eastern

Extended Trading

$15.68 -0.08 (-0.53%)

As of 04:10 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time